Hereditary Testing Market Size & Growth Forecast 2026–2035, By Segments (Disease Type, Technology), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Hereditary Testing Market size was around USD 8.17 Billion in 2025 and is slated to grow at a 8.4% CAGR from 2026 to 2035, surpassing USD 18.3 Billion by 2035. The industry revenue for 2026 is estimated at USD 8.78 billion.
Get more details on this report
Request Free Sample ReportHereditary Testing Market Intelligence Snapshot
Regional Market Dynamics
- Europe accounted for 36.46% of the market in 2025, supported by established diagnostic infrastructure, advanced laboratory capabilities, and broad clinical integration that sustains consistent testing demand across healthcare settings.
- Asia Pacific is projected to grow at a 9.49% CAGR as expanding laboratory capacity, improving molecular diagnostics access, and increasing clinician adoption accelerate hereditary testing across established and developing healthcare markets.
Segment Momentum
- Hereditary Non-cancer Testing accounted for 68.26% of the market in 2025 because it supports routine diagnosis and family risk evaluation across inherited cardiovascular, neurological, metabolic, and rare disorders.
- Cytogenetic is the fastest-growing technology segment as demand increases for assessing chromosomal abnormalities and structural variations alongside molecular testing to improve diagnostic resolution in complex hereditary conditions.
Market Expansion Drivers
- Rising prevalence of genetic disorders driving demand for early hereditary screening.
- Increasing adoption of molecular genetic testing improving diagnostic accuracy and disease detection.
- Expansion of preventive personalized medicine and insurance-backed genetic screening programs.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Top players in the hereditary testing market include Illumina, Inc. (United States), Thermo Fisher Scientific Inc. (United States), Myriad Genetics, Inc. (United States), Natera, Inc. (United States), Laboratory Corporation of America Holdings (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (United States), Fulgent Genetics, Inc. (United States).Regional and Segment Outlook
EuropeMarket Growth Drivers and Industry Trends
As inherited conditions are being identified more frequently through family history assessment, prenatal evaluation, and specialist referrals, clinicians are moving hereditary testing earlier in the care pathway rather than reserving it for symptom-driven diagnosis. This shift is driving demand for the hereditary testing market by increasing use of panel-based screening among individuals with known familial risk, reproductive planning needs, or suspected carrier status. In practice, higher disorder prevalence also prompts healthcare systems to formalize referral protocols for oncology, cardiology, neurology, and rare disease populations, which strengthens testing volumes and supports broader integration of hereditary testing into routine risk assessment.
Increasing adoption of molecular genetic testing improving diagnostic accuracy and disease detection
The growing use of molecular methods such as next-generation sequencing and targeted mutation analysis is influencing market adoption by making hereditary testing more clinically actionable and reducing uncertainty in complex cases. In the hereditary testing market, improved diagnostic precision encourages physicians to order tests with greater confidence when symptoms are nonspecific or when multiple inherited syndromes must be differentiated. This practical improvement in disease detection supports repeatable testing workflows in hospitals, specialty clinics, and diagnostic laboratories, while also increasing the value of broader test menus that can identify pathogenic variants earlier and guide follow-up care.
Expansion of preventive personalized medicine and insurance-backed genetic screening programs
Preventive care models are shifting hereditary testing from a reactive diagnostic tool to a structured screening service tied to long-term risk management, which is supporting market expansion through broader eligibility and more consistent reimbursement. In the hereditary testing market, insurance-backed programs reduce out-of-pocket barriers and make screening more feasible for asymptomatic individuals with family history indicators or population-level risk factors. That changes provider behavior in practice: primary care networks, women’s health providers, and specialty clinics are more likely to incorporate hereditary risk evaluation into standard patient intake and prevention pathways when coverage is clearer and downstream intervention planning is established.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising awareness of genetic disorders | 2.50% | Short term (≤ 2 yrs) | North America, Europe | Medium | Fast |
| Advancements in next-generation sequencing (NGS) technologies | 3.00% | Medium term (2–5 yrs) | North America, Asia Pacific | Low | Moderate |
| Increasing accessibility of hereditary testing in emerging markets | 2.90% | Long term (5+ yrs) | Asia Pacific, Latin America | Low | Slow |
| Rising prevalence of genetic disorders driving demand for early hereditary screening | 2.30% | High | Europe, North America | High | Near Term |
| Increasing adoption of molecular genetic testing improving diagnostic accuracy and disease detection | 1.90% | High | Europe, North America, Asia Pacific | High | Mid Term |
| Expansion of preventive personalized medicine and insurance-backed genetic screening programs | 1.60% | High | North America, Europe | Medium | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
Europe held a 36.46% share of the hereditary testing market in 2025, bolstered by established diagnostic infrastructure, broad clinical integration of genetic screening, and strong use of testing within preventive and specialist care pathways. The region’s leadership is aided by the practical availability of advanced laboratory capabilities and structured referral networks, which help move hereditary risk assessment from niche use into more routine oncology, prenatal, and family-history-based testing settings. This operating environment sustains consistent test volumes and supports continued demand across hospital, specialty clinic, and diagnostic laboratory channels.
Asia Pacific is projected to expand at a 9.49% CAGR over the forecast period, with the hereditary testing market gaining momentum as access to molecular diagnostics improves and healthcare systems broaden their use of earlier disease-risk identification. Growth is being fueled by rising adoption of genetic testing in urban care centers, expanding laboratory capacity, and increasing familiarity among clinicians with hereditary risk evaluation in patient management. As testing becomes more accessible in practice and awareness of inherited disease susceptibility strengthens, regional uptake is accelerating across both established and developing healthcare markets.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Evidence IntegrationGermany prioritizes hereditary testing within regulated clinical settings, with healthcare providers emphasizing evidence-based genetic screening and counseling services. The country is expanding the use of hereditary diagnostics in cancer management and rare disease identification through hospital-led initiatives.
France 🇫🇷
Public Health Genomics FocusFrance is incorporating hereditary testing into national strategies for cancer prevention and rare disease management. The country is emphasizing standardized genetic testing pathways and strengthening access to counseling services to support the broader use of hereditary diagnostics in clinical practice.
Italy 🇮🇹
Specialized Diagnostics NetworksItaly relies on specialized genetic centers and hospital networks to expand hereditary testing services. Increased attention to inherited cancer syndromes and family-based screening programs is encouraging broader use of genetic diagnostics within multidisciplinary care settings.
Japan 🇯🇵
Preventive Screening ExpansionJapan is increasing the use of hereditary testing to support early disease detection and personalized treatment planning, particularly in oncology. Growing interest in genomic medicine programs is encouraging broader adoption of genetic counseling and targeted hereditary testing services across healthcare institutions.
South Korea 🇰🇷
Digital Genomics EcosystemSouth Korea is combining advanced diagnostics infrastructure with digital healthcare platforms to improve access to hereditary testing services. The market is benefiting from investments in precision medicine and increasing use of genomic data to guide disease risk assessment and treatment decisions.
United States 🇺🇸
Precision Genomics AdoptionThe U.S. hereditary testing market is centered on expanding preventive genomics programs and integrating genetic testing into oncology and reproductive care pathways. Demand is increasingly supported by direct-to-consumer testing providers and healthcare systems seeking earlier identification of inherited disease risks.
Segment Leadership and Growth Trends
Hereditary Testing Market Share (%), Disease Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportHereditary Non-cancer Testing held the strongest position in the hereditary testing market in 2025, accounting for a 68.26% share. Its leadership is aided by the broad clinical use of genetic testing across inherited cardiovascular, neurological, metabolic, and rare disorders, where early identification can directly influence long-term disease management and family screening decisions. The hereditary testing market continues to see steady demand for Hereditary Non-cancer Testing because these applications are embedded across a wide range of diagnostic pathways rather than being concentrated in a narrower screening context.
Hereditary Cancer Testing is emerging as the fastest-growing segment in the hereditary testing market as clinical practice places greater emphasis on identifying inherited cancer risk earlier in the care pathway. Growth is being reinforced by rising use of genetic risk assessment to guide preventive surveillance, treatment selection, and cascade testing among family members. Compared with non-cancer applications, Hereditary Cancer Testing is gaining momentum from its increasingly direct role in oncology decision-making, which is making adoption more urgent and operationally relevant across care settings.
Technology Segment Analysis: Molecular Testing (Largest Segment) vs Cytogenetic (Fastest-Growing Segment)
Molecular Testing led the hereditary testing market in 2025 with a 57.09% share, reflecting its central role in detecting gene-level variants linked to inherited disorders. Its continued dominance comes from routine applicability across a wide range of hereditary conditions, where precise mutation identification is essential for diagnosis, carrier screening, and family risk evaluation. In the hereditary testing market, Molecular Testing remains the preferred technology because it aligns closely with the clinical need for targeted, actionable genetic information in day-to-day testing workflows.
Cytogenetic is the fastest-growing technology segment in the hereditary testing market, influenced by expanding use in cases where chromosomal abnormalities and structural variations need to be assessed alongside sequence-level findings. Its growth relative to other technologies is aided by the practical need for broader genomic characterization in more complex hereditary conditions, especially when molecular methods alone may not capture the full genetic picture. As testing strategies become more comprehensive, Cytogenetic is gaining traction through its complementary value in improving diagnostic resolution.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Disease Type | Hereditary Cancer Testing, Hereditary Non-cancer Testing | Hereditary Non-cancer Testing | Hereditary Cancer Testing |
| Technology | Cytogenetic, Biochemical, Molecular Testing | Molecular Testing | Cytogenetic |
Competitive Landscape and Market Positioning
1. Illumina Inc. (United States)
2. Thermo Fisher Scientific Inc. (United States)
3. Myriad Genetics Inc. (United States)
4. Natera Inc. (United States)
5. Laboratory Corporation of America Holdings (United States)
6. F. Hoffmann-La Roche Ltd. (Switzerland)
7. Agilent Technologies Inc. (United States)
8. Fulgent Genetics Inc. (United States)
Expanding precision medicine initiatives are advancing the hereditary testing market, with increasing investment in next-generation sequencing and advanced genetic analysis technologies. Continuous research is improving testing accuracy while expanding the role of hereditary screening in preventive healthcare and personalized treatment planning.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| GeneDx, LLC | Jun-25 | GeneDx partnered with Galatea Bio and Fabric Genomics to develop integrated hereditary cancer testing panels incorporating polygenic risk scores for breast, colorectal, and prostate cancers. The collaboration enhances precision in hereditary risk assessment by combining genomic sequencing with advanced risk modeling approaches. |
| Fulgent Genetics, Inc. | Feb-25 | Fulgent Genetics partnered with Foundation Medicine to launch FoundationOne Germline and FoundationOne Germline More in the U.S. The collaboration expands access to hereditary germline testing using integrated genomic platforms, strengthening clinical adoption of hereditary cancer screening tools in precision oncology workflows. |
| Guardant Health | May-25 | Guardant Health introduced the Guardant Hereditary Cancer test, expanding its portfolio into germline risk profiling for hereditary cancer assessment. The launch strengthens its position in genetic diagnostics by integrating hereditary risk evaluation into broader oncology-focused testing capabilities. |
| Oxford Nanopore Technologies | Sep-25 | Oxford Nanopore Technologies launched a 258-gene hereditary cancer panel designed to expand inherited cancer risk detection. The development enhances genomic coverage for hereditary testing applications, supporting more comprehensive genetic screening for oncology risk assessment. |
| Natera, Inc. | Dec-24 | Natera introduced the iPRS integrated polygenic risk score for breast cancer in partnership with MyOme, integrated with its Empower hereditary cancer test. The development enhances hereditary cancer risk stratification by combining germline testing with polygenic risk modeling to improve predictive accuracy in clinical screening workflows. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Hereditary Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Hereditary Testing Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow big is the hereditary testing market?
How is the hereditary testing industry projected to perform over the next decade?
How is expanding use of preventive genetic screening influencing adoption of hereditary testing in clinical practice?
Why is molecular diagnostic advancement accelerating clinical reliance on hereditary testing results?
Why does Hereditary Non-cancer Testing dominate the hereditary testing market?
Which technology segment is growing fastest in the hereditary testing market?
Why does Europe lead the hereditary testing market?
What is driving rapid growth in the hereditary testing market across Asia Pacific?
Who are the major participants shaping the hereditary testing landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization